3.4 Clinical characteristics and Imatinib Cssmin
Currently, the recommended dosage of imatinib targeted therapy is 400 mg/d. The difference between the neoadjuvant treatment group (male=6; female=3) and the adjuvant treatment group (male=4; female=5) was evaluated at the dosage of 400 mg/d. The Cssmin of two groups was similar (p=0.402, figure 4).
Considering no significant difference in Cssmin of imatinib between above two group, correlation between Cssmin and gender, age, Body Mass Index (BMI), medication duration, primary tumor site of 18 patients receiving 400 mg/d imatinib were compared, respectively. As in figure 5, significant difference was observed in Cssmin of imatinib between female and male patients. The median value of women was significantly higher than that of men (1998 ng/mL vs 1468 ng/mL, p=0.016). There was no correlation between Cssmin and age (r=-0.028, p=0.911), BMI (r=0.098, p=0.700), medication duration (r=-0.069, p=0.787).